- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00717652
Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma (melasma)
Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The melasma is a common hipermelanosis, acquired, symmetrical, with irregular occurring in areas such as photo-exposed face, forehead and temples, can affect the eyelids and tion. The facial regions most affected are: zigomatic (82.4%), parotid (64.7%), front (64.7%), mandible (35.3%) and nasal (35.3%). The injuries of melasma is variable increase of epidermal melanin and inflammatory infiltrate of mild to moderate intensity. Treatment with compounds such as hydroquinone and derivatives, tretinoin, corticosteroids moderate or combination of them all have shown good results, diminishing the training, reducing the stability and promoting the destruction of melanocytes. The primary objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) manufactured by Glenmark Laboratory, and as the comparator drug product Triluma ® (hydroquinone + fluocinolone + tretinoin), in the treatment of epidermal melasma through parameters of clinical course of the disease (improves) and its security.
Patients who are included in the study will be randomly and automatically receive one of the treatments (New association or Triluma ®), which should use for 12 weeks. The products should be applied in the regions affected once a day, during night.
The evaluation of clinical improvement, as well as security, will be held on periodic visits, as described below, which will be held the record and supply of medicines to patients.
In each visit, beyond the clinical examination of photographs and large, it filled the Area and Severity Scale (Melasma Area and Severity Index - MASI), which quantifies the melasma and will be the main tool of control of clinical improvement.
At the end of the study, data will be compared, showing no inferiority or inferiority of clinical drug testing in relation to the comparator.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
S
-
Valinhos, S, Brazil, 13270000
- LAL Clínica Pesquisa e Desenvolvimento Ltda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women adults aged more than 18 years;
- Patients suffering from melasma Epidermal the face of mild and moderate;
- Patients who have not done any treatment for melasma in the 3 months preceding the study;
- Patients with good mental and physical health;
- Patients who agree with the purposes of the study and sign the TCLE.
Exclusion Criteria:
- Patients with skin diseases other than melasma, which interfere in clinical evaluation as hemangiomas and queloides;
- Patients with melasma skin or mixed;
- Patients with sensitivity to agents hipopigmentantes;
- Patients with sensitivity to fotoprotetores;
- Patients who are pregnant or breastfeeding;
- Patients who, at the discretion doctor, are not able to participate in the study;
- Patients who have carried out any treatment for melasma in the 3 months preceding the study
- Patients who do not agree with the terms described in the Statement of Informed Consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
arbutin, tretinoin, triamcinolone
|
arbutin, tretinoin, triamcinolone
|
Active Comparator: 2
Triluma
|
Hydroquinone, Fluoncinolone, Tretinoin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone)in the treatment of epidermal melasma.
Time Frame: arbutin triamcinolone tretinoin
|
arbutin triamcinolone tretinoin
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATTGLE0508
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melasma
-
Mesoestetic Pharma Group S.L.Completed
-
ConBio, a Cynosure CompanyCompleted
-
University of Nove de JulhoRecruiting
-
Jinnah Postgraduate Medical CentreActive, not recruiting
-
China Medical University HospitalCompleted
-
VIST - Faculty of Applied SciencesActive, not recruiting
-
China Medical University HospitalApollo Medical Optics, LtdCompleted
-
Combined Military Hospital AbbottabadCompleted
-
Northwestern UniversityCompleted
-
Centre Hospitalier Universitaire de NiceCompleted
Clinical Trials on arbutin, tretinoin, triamcinolone
-
SP Nutraceuticals Inc.Canadian Glycomics Network (GlycoNet)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)Completed
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)CompletedCervical Cancer | Precancerous/Nonmalignant ConditionUnited States
-
Peking University Third HospitalActive, not recruitingOsteoarthritis, KneeChina
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruiting
-
Merete HaedersdalCompletedStriae DistensaeDenmark
-
Taro Pharmaceuticals USACompletedA Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne VulgarisAcne VulgarisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
University of UtahNot yet recruitingMetastatic Colon Cancer | Metastatic Rectum CancerUnited States